conjugated estrogens and bazedoxifene

G03CC07

Forms & Strengths

Adult Dosing

Treatment of moderate to severe vasomotor symptoms associated with menopause: 1 tablet (0.45 mg/20 mg) orally once daily
Prevention of postmenopausal osteoporosis: 1 tablet (0.45 mg/20 mg) orally once daily

Pediatric Dosing

Indications

Treatment of moderate to severe vasomotor symptoms associated with menopause in women with a uterus
Prevention of postmenopausal osteoporosis in women with a uterus

Mechanism of Action

Conjugated estrogens bind to estrogen receptors, reducing elevated gonadotropin levels and relieving vasomotor symptoms
Bazedoxifene is a selective estrogen receptor modulator (SERM) that acts as an estrogen agonist in bone and antagonist in the uterus, reducing the risk of endometrial hyperplasia associated with estrogens

Contraindications

Undiagnosed abnormal genital bleeding
Known, suspected, or history of breast cancer
Known or suspected estrogen-dependent neoplasia
Active or history of venous thromboembolism (deep vein thrombosis or pulmonary embolism)
Active or history of arterial thromboembolic disease (stroke, myocardial infarction)
Known hepatic impairment or disease
Known protein C, protein S, or antithrombin deficiency, or other thrombophilic disorders
Known or suspected pregnancy

Adverse Reactions

Drug Interactions

CYP3A4 inducers (e.g., rifampin, carbamazepine, phenobarbital) may increase estrogen clearance and decrease efficacy
CYP3A4 inhibitors (e.g., erythromycin, clarithromycin, ketoconazole) may increase estrogen exposure
Concomitant use with other estrogen-containing products or SERMs is not recommended
May alter the effectiveness of anticoagulant and antidiabetic therapies

Curated Content: Needs Vetting Before Put to Clinical Use